Quarterly report pursuant to Section 13 or 15(d)

STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY

v3.20.1
STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Common stock
Additional Paid in Capital
Accumulated Deficit
Total
Beginning Balance at Dec. 31, 2018 $ 16 $ 62,593 $ (23,720) $ 38,889
Beginning Balance (in shares) at Dec. 31, 2018 15,663,221      
Stock-based compensation   682   682
Exercise of stock options   1   1
Exercise of stock options (in shares) 2,581      
Net loss     (7,204) (7,204)
Ending Balance at Mar. 31, 2019 $ 16 63,276 (30,924) 32,368
Ending Balance (in shares) at Mar. 31, 2019 15,665,802      
Beginning Balance at Dec. 31, 2019 $ 18 83,565 (56,688) $ 26,895
Beginning Balance (in shares) at Dec. 31, 2019 18,087,382     18,087,382
Issuance of common stock, net of issuance costs $ 2 68,809   $ 68,811
Issuance of common stock, net of issuance costs (in shares) 2,300,000      
Purchase and cancellation of shares from BioXcel Corporation   (9,024)   $ (9,024)
Purchase and cancellation of shares from BioXcel Corporation (in shares) (300,000)     (300,000)
Stock-based compensation   776   $ 776
Exercise of stock options   39   39
Exercise of stock options (in shares) 95,000      
Net loss     (14,911) (14,911)
Ending Balance at Mar. 31, 2020 $ 20 $ 144,165 $ (71,599) $ 72,586
Ending Balance (in shares) at Mar. 31, 2020 20,182,382     20,182,382